A Practical Guide to Data Monitoring Committees in Adaptive Trials

被引:10
作者
Sanchez-Kam, Matilde [1 ]
Gallo, Paul [2 ]
Loewy, John [3 ]
Menon, Sandeep [4 ,5 ]
Antonijevic, Zoran [6 ]
Christensen, Jared [4 ]
Chuang-Stein, Christy [7 ]
Laage, Thomas [8 ]
机构
[1] Arena Pharmaceut Inc, Biostat & Data Management, San Diego, CA 92121 USA
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] QPharmetra Inc, Biostat, Winchester, MA USA
[4] Pfizer Inc, BioTx Stat, Cambridge, MA USA
[5] Boston Univ, Dept Biostat, Boston, MA 02215 USA
[6] Cytel Inc, Strateg Consulting, Cambridge, MA USA
[7] Pfizer Inc, Stat Res & Consulting Ctr, Kalamazoo, MI USA
[8] Regulatory Med Writing & Product Dev Consulting, Premier Res Grp, Boston, MA USA
基金
美国国家卫生研究院;
关键词
data monitoring committees; adaptive trials; practical guide; examples; RANDOMIZED CLINICAL-TRIALS; GROUP SEQUENTIAL TRIALS; DOSE-RANGING TRIALS; SAMPLE-SIZE; SIGNATURE DESIGN; INTERIM ANALYSES; STRATEGIES; CANGRELOR; SELECTION; PATIENT;
D O I
10.1177/2168479013509805
中图分类号
R-058 [];
学科分类号
摘要
Adaptive clinical trials require access to interim data to carry out trial modification as allowed by a prespecified adaptation plan. A data monitoring committee (DMC) is a group of experts that is charged with monitoring accruing trial data to ensure the safety of trial participants and that in adaptive trials may also play a role in implementing a preplanned adaptation. In this paper, we summarize current practices and viewpoints and provide guidance on evolving issues related to the use of DMCs in adaptive trials. We describe the common types of adaptive designs and point out some DMC-related issues that are unique to this class of designs. We include 3 examples of DMCs in late-stage adaptive trials that have been implemented in practice. We advocate training opportunities for researchers who may be interested in serving on a DMC for an adaptive trial since qualified DMC members are fundamental to the successful execution of DMC responsibilities.
引用
收藏
页码:316 / 326
页数:11
相关论文
共 51 条
[11]   Some drop-the-loser designs for monitoring multiple doses [J].
Chen, Y. H. Joshua ;
DeMets, David L. ;
Lan, K. K. Gordon .
STATISTICS IN MEDICINE, 2010, 29 (17) :1793-1807
[12]   ON THE INDEPENDENCE OF DATA MONITORING COMMITTEE IN ADAPTIVE DESIGN CLINICAL TRIALS [J].
Chow, Shein-Chung ;
Corey, Ralph ;
Lin, Min .
JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2012, 22 (04) :853-867
[13]   Sample size reestimation: A review and recommendations [J].
Chuang-Stein, Christy ;
Anderson, Keaven ;
Gallo, Paul ;
Collins, Sylva .
DRUG INFORMATION JOURNAL, 2006, 40 (04) :475-484
[14]   Modification of sample size in group sequential clinical trials [J].
Cui, L ;
Hung, HMJ ;
Wang, SJ .
BIOMETRICS, 1999, 55 (03) :853-857
[15]  
Cutlip D, 2008, APPL CLIN TRIALS, V17, P58
[16]   Sample size recalculation using conditional power [J].
Denne, JS .
STATISTICS IN MEDICINE, 2001, 20 (17-18) :2645-2660
[17]   A Simulation Study to Compare New Adaptive Dose-Ranging Designs [J].
Dragalin, Vladimir ;
Bornkamp, Bjoern ;
Bretz, Frank ;
Miller, Frank ;
Padmanabhan, S. Krishna ;
Patel, Nitin ;
Perevozskaya, Inna ;
Pinheiro, Jose ;
Smith, Jonathan R. .
STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2010, 2 (04) :487-512
[18]  
Eastern Cooperative Oncology Group (ECOG), DAT MON COMM POL
[19]  
Ellenberg S., 2002, DATA MONITORING COMM
[20]   Adaptive signature design: An adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients [J].
Freidlin, B ;
Simon, R .
CLINICAL CANCER RESEARCH, 2005, 11 (21) :7872-7878